BiotechTube

Pembrolizumab + Mogamulizumab

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cutaneous T Cell Lymphoma

Conditions

Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome

Trial Timeline

Dec 6, 2023 → Apr 1, 2027

NCT ID
NCT05956041

About Pembrolizumab + Mogamulizumab

Pembrolizumab + Mogamulizumab is a phase 2 stage product being developed by Merck for Cutaneous T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05956041. Target conditions include Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05956041Phase 2Recruiting

Competing Products

20 competing products in Cutaneous T Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
85
ONTAKEisaiApproved
85
E7777 9 mcg/kgEisaiPhase 3
77
ONTAKEisaiApproved
85
MogamulizumabKyowa KirinApproved
85
Mogamulizumab + Brentuximab vedotinKyowa KirinPhase 1
33
MogamulizumabKyowa KirinPhase 2
52
KW-0761 + VorinostatKyowa KirinPhase 3
77
EnzastaurinEli LillyPhase 2
52
Clopidogrel + TicagrelorAstraZenecaApproved
85
PembrolizumabMerckPhase 2
52
Comparator: vorinostatMerckPre-clinical
23
PembrolizumabMerckPhase 2
52
TR701 FAMerckPhase 2
52
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 MonthsMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Tulisokibart + PlaceboMerckPhase 2
52
Aspirin + Ipilimumab + PembrolizumabMerckPhase 2
52
TR-701 FA + LinezolidMerckPhase 3
77
Pimasertib + DacarbazineMerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85